Nice to see you're on to it before the herd comes running Agent....

Nice to see you're on to it before the herd comes running Agent. As Matchbox said Sth Cross had already set an 18c target and now that we have an adviser from the Bell/Sth Cross team on the board I've no doubt that target will be set a lot higher post July 1. ;)

I'm very bullish on this if you haven't already noticed. One of the few forums over the past 12 months where one couldn't be accused of ramping due to no interest. (also due to very tight register and no liquidity)

In last year @ 2c during traditional May/June season market sell-off and on the back of an announcement which encouraged a further downward spiral. Had planned to sell at 10c but things have changed to justify a higher price now.

With regards to your other post:

Prof Ian Frazer's Coridon is focussed on vaccines for a range of infectious diseases and cancers in humans. Product development is currently focused on herpes virus vaccines as you know which is being partnered with PRR.

This whole new diversified health group hasn't announced Coridon's development programs yet but no doubt there'll be 2 big announcements from that corner before the year's out.

Imo, Mr Forrest would certainly be aware of PRR because of his close links to Ian Frazer. He probably also personally knows brother, Neil who as you are most aware is PRR's Chief Medical Officer.

Interestingly, Coridon has also compiled a table for maximising the antibody response for intra-dermal delivered DNA vaccines. Prof Frazer was previously on the scientific Advisory Board of my favorite neglected stock, OBJ, who, in my heavily researched opinion currently have the world's next generation and most advanced intra-dermal and transdermal drug delivery technologies.

As you mentioned, BioMD's lead product is the CardioCel patch which is a product sold to cardiologists, however prior to this T/O BioMD were a little strapped for the cash required to commercialise it. Problem solved. Allied is cashed up and is a medical device company which sells products to cardiologists so a win win situation there and I'd expect we should hear some news on this soon.

Imo another good point to make is the issue of discounted placements to the insto's and soph's when a company needs to raise capital. As you know I raised my own concern over PRR doing this recently, however should BioMD ever need to raise capital I highly doubt they will ever have to succumb to the insto sharks (who only ever serve to drive a sp down) when some of Australia's wealthiest long term investors are already on the register.

BioMD shareholders will always come first now.